TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01439724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy- (DMC, São Paulo, Brazil)
Description: Diode laser (DMC,São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100 mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (DMC, São Paulo, Brazil)
Description: The placebo (DMC, São Paulo, Brazil) was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
Study: NCT03023709

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone®
Description: quadrivalent, inactivated influenza virus vaccine, intramuscular

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist®
Description: quadrivalent, live, attenuated influenza vaccine, intranasal spray
Study: NCT02136706

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Myocardial Perfusion imaging with 10 minute waiting period
Description: After the Myocardial Perfusion Imaging testing the investigators will wait 10 minutes to take images and then wait the 30 minute standard of care time to take images.
Study: NCT03292575

Intervention type: DRUG
Intervention: Anticoagulants
Study: NCT04423510

Intervention type: PROCEDURE
Intervention: Crystallized phenol treatment
Study: NCT01995643

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Capsule
Description: GSE Capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Placebo Capsule
Study: NCT01424709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Docetaxel, CPT-11,Cisplatin
Description: Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine/cisplatin
Description: gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
Study: NCT02124486

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Participants randomised to the bariatric surgery arm of the trial will be referred to the surgery pathway according to NICE guidelines at Birmingham Heartlands Hospital (BHH), Heart of England NHS Foundation Trust.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietetic intervention
Description: Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers.
Study: NCT00737438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
Description: Patients with FDG avid locally advanced but resectable gastric or GEJ adenocarcinoma will receive preoperative therapy with epirubicin, cisplatin, capecitabine (ECX), and bevacizumab. Each cycle of therapy is 21 days. Near the completion of cycle 1 of therapy (eg during week 3, target days 18-21), patients will undergo a second FDG-PET/CT scan. Note, patients will hold capecitabine for 48 hours prior to the FDG-PET/CT scan.~Patients with a good metabolic response (eg. \> 35% reduction in FDG uptake at the primary tumor on the week 3 PET scan as compared with baseline FDG uptake) will continue ECX for 2 additional cycles (cycle 2 and 3).~Cycle 2 will be administered with bevacizumab and cycle 3 will be administered without bevacizumab. Patients will then proceed to surgery approximately 4-6 weeks following the completion of cycle 3. There is a 10-12 week time interval (eg. 70-84 days) between the last bevacizumab treatment and surgery.
Study: NCT00736814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given intravenously
Study: NCT00854542

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telepsychiatry-based Culturally Sensitive Collaborative Treatment
Description: T-CSCT: Patients in Group A will receive T-CSCT, which consists of Telepsychiatry-based Culturally Sensitive Psychiatry Assessment using the Engagement Interview Protocol (EIP) plus Care Management.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Telepsychiatry-based Culturally Sensitive Collaborative Treatment
Description: T-CSCT: Patients in Group A will receive T-CSCT, which consists of Telepsychiatry-based Culturally Sensitive Psychiatry Assessment using the Engagement Interview Protocol (EIP) plus Care Management.
Study: NCT04112420

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Trans-esophageal echocardiography
Description: The department registers an unplanned admission of a patient to the intensive care unit. The indication is verified again by the intensive care physician.~In this case, the patient is then admitted to the intensive care unit, supervised by an intensive care physician, orientated and initiated therapeutic and diagnostic measures.~As part of the planned transthoracic cardiac ultrasound examination, it is then selected whether the patient is suitable according to the patient's will and the inclusion or exclusion criteria.~After clarification, time to think and consent, the examination is then carried out according to the protocol by approved doctors of the Clinic for Anesthesia, intensive care and pain therapy. Followed by digital storage for the finding.~After the subsequent operation, the investigator determines whether knowledge of detected pathologies would have an effective influence on the anesthesiological procedure or not.
Study: NCT00929123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neural mobilization
Description: manual therapy technique known to directly stress the median nerve

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham neural mobilization
Description: sham technique mimicking the neural mobilization which is not specific to the median nerve

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: healthy controls
Description: People without carpal tunnel syndrome for comparison
Study: NCT01495975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Transitions Tool Kit
Description: Access to a remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), for the month after discharge.
Study: NCT00857883

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1521498 or placebo
Description: GSK1521498 is a mu-opioid receptor inverse agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1521498 or placebo
Description: GSK1521498 is a mu-opioid receptor inverse agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1521498 or placebo
Description: GSK1521498 is a mu-opioid receptor inverse agonist
Study: NCT01592682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smokefree counseling
Description: Smokefree counseling intervention involves group education sessions, follow-up phone calls, tobacco exposure lab report. Comparison is usual care with referral to local in-language smoking cessation services including quitline.
Study: NCT00946361

Intervention type: OTHER
Intervention: Examinations
Description: Growth hormone stimulation testing, Protein turnover, Dexa scan, Bone age x-ray
Study: NCT00808483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking skill training program
Description: 12 individualized training sessions containing functional exercises like walking, stair climbing, balance training and with supervision and guidance from a physiotherapist.
Study: NCT03439059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing Sedentary Behaviour Group
Description: Participants will be prompted to perform 10min of light physical activity (\>1.5 METS) 3x/day for 6 weeks
Study: NCT01976676

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: folic Acid
Study: NCT00722332

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepaGam B
Description: Hepatitis B Immunoglobulin
Study: NCT02680535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AuroShell particle infusion
Description: Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.
Study: NCT03920787

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inofolic Combi
Description: Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg. 2 capsules every day for 1 month.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules every day for 1 month
Study: NCT04439149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K-beta Inhibitor GSK2636771
Description: Given PO
Study: NCT04470271

Intervention type: OTHER
Intervention: Patients with hepatitis C lost follow up
Description: Patients with chronic HCV who were lost of follow up will be contacted by phone or email. At least 3 phone calls will be made on three different days. In case the patient is not contacted it will be considered lost of follow-up
Study: NCT03080454

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham Doublestim
Description: PathMaker MyoRegulator device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anodal Doublestim
Description: PathMaker MyoRegulator device
Study: NCT03500575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photopheresis
Description: • Treated group will receive ECP with Therakos online system. Each session consists in 1 treatment for 2 consecutive days. First session stars within 72 hours after transplantation followed by a session weekly for 3 time and 2 sessions for the next 2 months (6 sessions = 12 treatment)
Study: NCT00843531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 5 mg/day PO (oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 100 mg/day (oral)
Study: NCT01772160

Intervention type: OTHER
Intervention: Data collection
Description: HZ/PHN booklet, HZ/PHN file and logbook. HZ/PHN booklet will be completed by the patient and the HZ/PHN file and logbook will be completed by the participating general practitioner.
Study: NCT04391491

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuregulin-1β level in plasma
Description: Peripheral blood will be collected after randomization (plus or minus 3 days), the plasma will be assayed for neuregulin-1b, biomarkers of inflammation and fibrosis, NTproBNP

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuregulin-1β level in plasma
Description: Peripheral blood will be collected after randomization (plus or minus 3 days), the plasma will be assayed for neuregulin-1b, biomarkers of inflammation and fibrosis, NTproBNP

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuregulin-1β level in plasma
Description: Peripheral blood will be collected after randomization (plus or minus 3 days), the plasma will be assayed for neuregulin-1b, biomarkers of inflammation and fibrosis, NTproBNP

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuregulin-1β level in plasma
Description: Peripheral blood will be collected after randomization (plus or minus 3 days), the plasma will be assayed for neuregulin-1b, biomarkers of inflammation and fibrosis, NTproBNP
Study: NCT04680130

Intervention type: DRUG
Intervention: C-11 PiB
Description: Completing PET scan looking for amyloid protein

Intervention type: DRUG
Intervention: AV1451 Tau
Description: Completing PET scan looking for tau protein

Intervention type: DRUG
Intervention: C-11 ER176
Description: Completing PET scan looking for neuroinflammation
Study: NCT02570360

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: The EX participants will engage in supervised, individual treadmill exercise 3xs/wk at the UW Natatorium. Sessions will consist of a 5-minute warm-up followed by 30 minutes of a moderate to moderately-high intensity exercise and then finish with a 5-minute cool down. Questionnaires will be completed before and after exercise on a weekly basis.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: treatment-as-usual
Description: The control (standard care) participants will come to the UW-Natatorium on a weekly basis to complete questionnaires.
Study: NCT02460107

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study: NCT01076231

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton beam radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study: NCT05012657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point Partial
Description: The Point Partial partial finger prosthetic system consists of 1-4 ratcheting mechanical partial digits and mounting brackets
Study: NCT00142610

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin
Description: This is designed as a placebo controlled study of 500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks, on airway antioxidant levels in asthmatics.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin
Description: This is designed as a placebo controlled study of 500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks, on airway antioxidant levels in asthmatics.
Study: NCT01123850

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Copios
Description: Bone Void Filler
Study: NCT05007210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prenatal massage therapy
Description: Pregnant women in the intervention group had a whole body prenatal massage therapy every week between 30th and 34th gestational weeks (once a week, 5-weeks in total and 60-minutes each).Session content for the prenatal massage therapy group was created by the researcher who was 640-hours trained massaging midwife.It included 12 different massage techniques (Osborne 2015, Osborne 2021).Also, the session, which included deep tissue and Sweden massage methods, had been applied.Each session began with the pregnant woman in a side-lying position with standart special pillows (30-minutes for left, 30-minutes for right).EFM, BPP, vital signs, FHR evaluation were carried out for all participants per visiting the hospital for the study.BPP before and after prenatal massage therapy was evaluated by an obstetrician.A phone number was set for the study, and this phone number was used by the massaging midwife.The service has been provided for pregnant women to reach her whenever they want.
Study: NCT01601314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: At the beginning of the neurosurgery, the subjects are going to receive one 4gr bolus in Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Magnesium Sulfate 20 gr, in Sodium Chloride 1000 mL, lasting 24 hours, will be started.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: At the beginning of the neurosurgery, the subjects are going to receive a bolus of Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Sodium Chloride 1000 mL, lasting 24 hours, will be started.
Study: NCT02416674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abdominal wall transplantation
Description: transfer of abdominal wall tissues from an organ donor to a pacient with a large abdominal wall defect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressive Agents
Description: Recipients of abdominal wall transplants will need to receive global immunosuppression with tacrolimus, mycophenolate mofetil and prednisone.
Study: NCT03491956

Intervention type: DEVICE
Group type: OTHER
Intervention: DFPP
Description: Lipid levels,platelet function，and platelet RNA sequencing in hyperlipidemia patients before and after DFPP
Study: NCT02664220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-iodine irrigation
Description: Povidone-iodine (PVI) is an antiseptic solution consisting of polyvinylpyrrolidone with water, iodide, and 1% available iodine. It has bactericidal ability against a large array of pathogens, including those pathogens which commonly cause postoperative IAA in children with perforated appendicitis.~1% PVI will be used. Once the appendix has been removed and hemostasis ensured, the surgeon will perform the irrigation with 10cc/kg (minimum 100ml and maximum 1000ml) of 1% PVI. After completing the irrigation, the surgeon will suction out all intra-abdominal fluid into a suction canister.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No irrigation
Description: Patients allocated to the control group will not undergo intra-abdominal irrigation.
Study: NCT00512824

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: low calcium milk of 180 ml
Description: twice daily for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: regular milk of 180 ml
Description: twice daily for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: regular milk of 180 ml + probiotics
Description: twice daily for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: regular milk of 180 ml + probiotics
Description: twice daily for 24 weeks
Study: NCT00108524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carbohydrate ketogenic diet
Description: A low-carb diet limits carbohydrates - such as grains, starchy vegetables and fruit - and emphasizes dietary protein and fat.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Description: In addition to the low fat diet, Orlistat is taken 3 times daily.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat diet
Description: Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake
Study: NCT02870543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phytolacca decandra
Description: Treatment of bruxism

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phytolacca decandra
Description: Treatment of bruxism
Study: NCT03293199

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest tube drainage
Description: In this group, in the supine position and subsequent to prepping and draping and local anesthesia administration via lidocaine 2%, F16 or F20 (based on patients physical status) sterile plastic tube will be implemented at the level 4th or 5th intercostal space through the midaxillary line. Subsequently, the external end of the tube will be connected to water sealing bottle and water bubbles coming out will be considered as proper chest tube insertion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive needle aspiration
Description: In this group, prior to needle aspiration, patients will take the semi-supine position. Subsequent to local anesthesia via lidocaine 2%, as well as prepping and draping, G16 intravenous angiocath will be inserted through midclavicular line at the level 2nd or 3rd intercostal space. Air bubble inside the lidocaine syringe will be considered as needled entrance to pleural cavity, thus 5-10 cm of the angiocath will be import to inside of the cavity. The catheter needle will be removed and catheter will be fixed using sterile sticks. A three-way valve will be connected to external end of the catheter and a 50 ml syringe will be connected to the valve. The air suction will be performed using 50 ml syringe till end of the air suction or up to 3.5 liters of air suctioning.
Study: NCT03140254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N'-(1,10-decanediyldi-1(4H)-Pyridinyl-4-ylidene)-Bis-(1-octanamine) Dihydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03077178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Geriatric assessment
Description: Geriatric assessment, questionnaire assessment
Study: NCT04434066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy
Description: Participants will be randomized into either abdominal or vaginal morcellation at time of total laparoscopic hysterectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy
Description: Participants will be randomized into either abdominal or vaginal morcellation at time of total laparoscopic hysterectomy
Study: NCT04165083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT03631173

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical og radiological intervention, antibiotics
Description: Intervention might be a new drainage catheter, replacement of old drainage catheter, reoperation, somatostatin- and antibiotic administration.
Study: NCT02762994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-085